Abstract
The administration of colloids, and hydroxyehtyl starch (HES) in particular, in critically ill patients has been questioned by several studies, with different conclusions regarding outcomes and kidney injury. Older HES solutions have been shown to correlate significantly with acute kidney injury [1], but the question remains open for newer, lower molecular weight and lower MS preparations (tetrastarches). Recently, a Scandinavian trial has reported that 6 % HES 130/0.42 significantly increased mortality in patients with severe sepsis and septic shock [2]. To further assess safety and efficacy of HES solutions, the CHEST investigators have conducted a large-scale trial comparing 6 % HES 130/0.40 (Voluven) to normal saline in ICU patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
